<DOC>
	<DOCNO>NCT01480492</DOCNO>
	<brief_summary>During hepatitis B virus ( HBV ) infection host immune play important role.Recently many different antiviral therapy methods.Different antiviral therapy method show different effector.In order investigate whether antiviral therapy method especially method directly inhibit viral replication effect host immune investigator design study . The investigator want observe change host immune antiviral therapy patient chronic HBV infection , analyze relationship change antiviral effector drug .</brief_summary>
	<brief_title>Effect Antiviral Therapy Host Immune Patients With Chronic Hepatitis B Virus ( HBV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>inclusion criterion : 1865 year old chronic HBV infection HBeAg positive , HBV DNA 10E5 IU/mL ALT ≥2×UTL exclusion criterion : liver cancer liver failure pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>HBV</keyword>
	<keyword>Immune</keyword>
	<keyword>antiviral therapy</keyword>
</DOC>